We will have an abundant supply of Remdesivir by the second week of May: Biocon chief Kiran Mazumdar Shaw

Kiran:  I think what we need to do is to make sure that we alleviate the panic that there is today in hospitals and in people's minds. So, I think what we're doing, obviously, is ramping up production. Remdesivir is a drug that was licensed to a number of Indian companies. We've been one of them. And it is adequate supply, once you basically gear up production. The problem is that all of us slowed down production. Production was at a very, very low level because the first wave was seen to have subsided, and you know, that we are in a safe place.

I think we ought to have vaccinated much faster and then once again, I think we've missed an opportunity, in my view. And now we're paying the price for that because I've seen one thing that anybody who has taken even one shot of vaccine, even if they get re-infected, it is not severe. I think that would tell you how important it is to vaccinate. And, we are of course ramping up the production. I personally believe that by the second week of May, you will have an abundant supply of Remdesivir in the country. As far as Itolizumab and Tocilizumab are concerned, I think by end of May, early June you will have adequate supply to cater to the market. So I think you are going to be very challenged for 4-6 weeks and that is what we have to endure.

I think the hospitals are doing an amazing job, but doctors are getting fatigued, nurses are getting fatigued, because all these hospitals are being overwhelmed. And I think it is important for us to know that if anyone has been re-infected, you should not be rushing to the hospital.

Q: Do you think the government should have capped the prices of Remdesivir? Will it disincentivize manufacturers?

Kiran: I don't think they're going to really get affected by the price cap because the price that they've actually announced is something that I think most companies will be okay with. What really worries me is the price cap on vaccines. I think that is the biggest blunder that the government has made, in my view.

I think the government has made such a blunder because they have kept the price of vaccines at $2, whereas the international public price is $3. And they have actually put our vaccine makers at a disadvantage. This is ridiculous. I think our vaccine makers need to have a fair price. I think the government procuring at $2 is one thing. But I think they should understand that the private markets must be much higher, and they will pay much higher. This is a life-saving vaccine. And RT PCR test costing more than a vaccine is absurd. And the fact that people who take vaccines are willing to spend 1,000 rupees to get an antibody test is another absurdity.

So, I really don't know why the government is so hellbent on controlling vaccines. So, I'm very, very concerned that the government is refusing to admit that they made a mistake. And they are going to continue to hurt the sector. I don't know how they're going to address the pricing of the Sputnik vaccine, or how they're going to allow the import of other vaccines, which now they're allowing through an automatic approval route because nobody's going to be willing to sell the vaccine at 150 rupees.

Q: Shouldn't there be more clarity on the number of orders, advance paid, rollout- the next steps?

Kiran: First and foremost, I think they had many months to prepare for vaccine deployment. They should have got into vaccine procurement, they should have worked out how many doses each state government ought to get in a phased way. I really don't know when all that planning was done. If it was, then why is there so much, panic and chaos right now? And of course, we have given away many, many vaccines to other countries.

So, you know, I don't think there was a clear understanding that you know, we do need to vaccinate fast. And that, you know, we could have actually, certainly exported vaccines once we started getting into a safe place.

Q: But isn't that also because none of us anticipated that the second wave would hit us with such ferocity?

Kiran: Yes, that is a fact. Even though there were many epidemiologists who were actually forecasting a second, but nobody was willing to accept it. All of us were under the impression that we had overcome it and I must admit even I thought this; this is what is happening, that there's something very, very unique about the Indian environment and the Indian DNA or whatever you might call it, that, you know, we are not seeing the kind of disease burden that other countries are seeing. But then, you know, this has actually taken us by storm.

And I think that is why I think we need to vaccinate at scale. I've been really, really making a big plea to the government saying vaccinate those who are really exposed and not just the elderly.

Q: Is it also because of the variant? The double mutant UK strain...

Kiran: Will you please understand that any virus undergoes mutations? For instance, you know, if you look at the influenza virus, it could just be a mutant of the Spanish one, which happened a century ago. So, it keeps continuing cogeneration also has now taken the world by storm, and this is a new virus, and I wouldn't be surprised if it keeps on mutating. And it'll become like another flu. You know, it has to go through many, many mutations.

So, mutations will happen. But we do need to find a way of basically dealing with this virus and I think the only way we can deal with this virus is through vaccination.

Kiran: I don't agree with that at all. Because I think that right now, we are not dealing with vaccine production. Today, we have enough arrangements between Indian vaccine makers and overseas vaccine makers.

Q:  Is it also a funding issue? Last week, Adar Poonawalla said he needed Rs 3,000 crores to ramp up manufacturing. Some believe that allowing companies to give CSR funds for this could be a solution. The Govt did give a grant to Bharat Biotech but that's a small one.

Kiran: I certainly believe that the government has to understand that if they want to ramp up manufacturing in a big way, then it's not about 65 crores, it is going to require a few 1,000 crores each. So you will need a few billion dollars to support the vaccine manufacturers. But I think more than anything else, given better pricing to the vaccine makers for the private market.

Q: Finally, in terms of the next steps, on the treatment protocol side, you said some of these drugs should be available in the coming weeks. But from a vaccine perspective, where do you see this going?

Kiran: It is difficult to answer that question because we just don't know what the COVID task force is thinking about. I mean, are they going to allow us to import vaccines, like the mRNA vaccine? Because those are available for a much higher price.

If we have Sputnik approved, how are we going to deploy it because they are refusing to consider Rs 150 as a price? So you know, they really shot themselves in the foot. So. I really want to know, how are we going to ramp up vaccination, and of course, all the vaccine makers are trying to ramp up in a big way.  And I personally believe that vaccine deployment ought to be decentralized. I think state govt must be given some kind of flexibility to decide how they want to prioritize.